









Markets
/
Stocks
/
nasdaq-calc
/

CalciMedica Inc

CALC

3.020USD

-0.190-5.92%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

42.20MMarket Cap

LossP/E TTM



CalciMedica Inc

3.020

-0.190-5.92%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

225 / 506

Overall Ranking

361 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

16.000

Target Price

+398.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

Fairly Valued

The company’s latest PE is -1.88, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 10.50M shares, decreasing 1.12% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 339.15K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.31.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.00, which is -87.44% below the recent high of -0.25 and -1.17% above the recent low of -2.02.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 225/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for CalciMedica Inc is 15.50, with a high of 20.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

16.000

Target Price

+398.44%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

CalciMedica Inc

CALC

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.30, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.75 and the support level at 2.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.30

Change

-0.28

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.040

Neutral

RSI(14)

49.411

Neutral

STOCH(KDJ)(9,3,3)

43.129

Neutral

ATR(14)

0.349

Low Volatility

CCI(14)

-68.009

Neutral

Williams %R

63.964

Sell

TRIX(12,20)

0.490

Sell

StochRSI(14)

40.974

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

3.079

Sell

MA10

3.215

Sell

MA20

3.075

Sell

MA50

3.024

Sell

MA100

2.378

Buy

MA200

2.399

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 75.62%, representing a quarter-over-quarter increase of 0.57%. The largest institutional shareholder is The Vanguard, holding a total of 339.15K shares, representing 2.43% of shares outstanding, with 3.51% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Sanderling Ventures

2.41M

Alafi Capital Company, LLC

1.30M

Deerfield Management Company, L.P.

1.30M

Soleus Capital Management, L.P.

783.90K

Valence Investments SPV IV LLC

739.33K

Aisling Capital Management LP

521.11K

Lytton (Laurence W)

468.94K

-5.24%

Pengana Capital Group Limited

449.00K

Wilson (Robert N)

417.53K

The Vanguard Group, Inc.

Star Investors

339.15K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.09, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.